An update to the original article posted 15 November 2018 and the follow up of 18 December 2018.

As advised via PHARMAC tender of 30 April 2018 there is to be a change in the listing and future sole supply.

New listing from 1 December 2018

Bimatoprost-Multichem Eye Drops 0.03% 3 ml OP Pharmacode  2545128   Schedule price $3.30

Incumbent brand

Bimatoprost-Actavis Eye Drops 0.03% 3 ml OP        Pharmacode 2497069 Schedule price $3.65

Reference pricing will apply to the incumbent from 1 February 2019.  (Note:- in association with Teva, ProPharma / PWR reduced the price to $3.00 from 4 December 2018. Therefore there will be no part charge come reference pricing 1 February 2019)

HML (Hospital Supply Status) commences 1 February 2019.  CSS (Community Supply Status) commences 1 May 2019.

As of the date of this notification ProPharma / PWR cannot accept Bimatoprost-Actavis  for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Click here to review the analysis showing the benefit to you of staying with the incumbent until 30 April 2019 or stock is exhausted – whichever comes first.

There is a serious margin improvement by staying with Bimatoprost-Actavis until stocks are depleted.

Once again we need your support to ensure stock in the supply chain moves through to effectively ensure no losses are incurred.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close